Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bristol Myers Squibb Co (BMY), Momenta Pharmaceuticals, Inc. (MNTA): White Collar Criminals Love Biotech Stocks

It’s understandably very tempting for people with inside information to trade biotech stocks. With the potential for overnight doubles and triples after binary events, there’s quick money to be made.

They shouldn’t. It’s illegal. But that doesn’t stop them.

Some even get caught. These are their stories. There’s a lesson — beyond that you could go to jail — in their actions.

Baking cupcakes in jail
Perhaps the most famous insider trading involves Martha Stewart who was sentenced to five months in the pen for selling shares in ImClone Systems, allegedly on a tip from her stock broker who figured out that ImClone’s CEO Sameul Waksal and his daughter had sold shares right before the Food and Drug Administration decided not to accept ImClone’s application to market Erbitux.

She avoided a loss of $45,673 by selling her shares prior to the 16% drop after the FDA’s decision was announced publicly. Hope the inmates enjoyed the cupcakes.

Bristol Myers Squibb Co. (NYSE:BMY)

How to avoid insider trading
I’d start by not doing Internet searches on insider trading detection and reading articles titled “Ways to Avoid Insider Trading” — unlike Robert Ramnarine, who reportedly did just that. The executive at Bristol Myers Squibb Co. (NYSE:BMY) has admitted to using his inside knowledge of Bristol Myers Squibb Co. (NYSE:BMY)’s potential takeover targets to buy options in the companies, including Amylin Pharmaceuticals, prior to the announcement of the acquisitions.

Really on the inside
It’s not too hard to figure out whether drugs will be approved if, like Cheng Yi Liang, you work at the FDA. Liang reportedly racked up $3.6 million in profits from his inside knowledge.

In some cases, he played both sides of the bet, like for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) when he shorted the company before the FDA delayed approval of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)’s generic version of Sanofi SA (ADR) (NYSE:SNY)‘s Lovenox in 2007 and then went long when the drug was finally approved in 2010.

The big profits came when most investors weren’t expecting approvals. Liang’s biggest gain came from approval of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)‘ Fanapt after the surprise approval. No one saw that one coming.

And the list goes on
Last year, the SEC charged a bunch of high school friends who worked at Celgene Corporation (NASDAQ:CELG), Sanofi SA (ADR) (NYSE:SNY), and Stryker Corporation (NYSE:SYK) who reportedly shared non-public information about earnings announcements, regulatory decisions, and takeover targets, including Sanofi’s takeout of Chattem for a 34% premium.

The government also charged a hedge fund manager for selling shares of Elan Corporation, plc (ADR) (NYSE:ELN) who got tipped off to the failure of the company’s Alzheimer’s drug bapineuzumab by a member of the Safety Monitoring Committee in charge of the clinical trial.

You don’t have inside information, but…
The attraction to the biotech industry for criminals is the same reason it appeals to lawful investors. The binary events provide for substantial upside. Just keep in mind that, unlike those with inside knowledge, you’re also exposed to the downside. Keep your purchases and shorts to a reasonably small percentage of your portfolio.

Will MannKind Corporation (NASDAQ:MNKD)‘s disruptive technology revolutionize the way diabetes is treated around the world — or will the FDA put the kibosh on this product before it even hits the market?

The article White Collar Criminals Love Biotech Stocks originally appeared on

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Celgene and Momenta Pharmaceuticals. The Motley Fool owns shares of Momenta Pharmaceuticals.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!